Beta Bionics, Inc. BBNX
21.51
(0.25)
(1.15%)
as of 25 Sep
- Market cap
- $1.2B
- P/E
- 0.0×
Follow BBNX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+7 more TTM periods Free account |
(169.86%) | (346.51%) | (22.71%) | (26.16%) | |
| (47.17%) | (30.60%) | (20.68%) | (23.45%) | ||
ROIC |
(64.88%) | (65.51%) | (67.46%) | (68.47%) | |
Return on Tangible Assets |
(30.89%) | (29.81%) | (28.28%) | (33.82%) | |
Average Days of Receivables |
47.55 | 62.32 | 52.15 | 55.37 | |
Free Cash Flow per Share |
(1.39) | (8.22) | (7.60) | (7.59) | |
Free Cash Flow |
(60.53) | (332.96) | (337.86) | (338.15) | |
Capital Expenditures |
(3.95) | (282.03) | (283.08) | (282.34) | |
Piotroski F-Score |
1.00 | 4.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(10.81%) | (10.05%) | (11.63%) | (12.77%) | |
Accounts Receivable Turnover |
11.08 | 6.89 | 8.89 | 8.08 | |
Accounts Payable Turnover |
14.32 | 11.39 | 16.37 | 11.31 | |
Inventory Turnover |
3.73 | 2.55 | 2.39 | 2.41 | |
Average Days of Payables |
40.42 | 40.80 | 17.91 | 39.37 | |
Days of Inventory on Hand |
184.57 | 177.32 | 183.35 | 175.97 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
38.24% | 34.70% | 34.07% | 32.70% | |
Selling, General and Administrative Expense of Revenue |
93.72% | 92.20% | 93.21% | 95.36% | |
Share Based Compensation of Revenue |
15.39% | 16.34% | 17.22% | 17.82% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.70 | 0.82 | 0.76 | |
Depreciation/Fixed assets |
0.33 | 0.33 | 0.32 | 0.52 | |
Capex/Depreciation |
(1.60) | (98.10) | (86.89) | (50.11) | |
Revenue per Share |
2.03 | 2.47 | 2.48 | 2.67 | |
Operating CF per Share |
(1.30) | (1.26) | (1.23) | (1.25) | |
Capex per Share |
(0.09) | (6.96) | (6.37) | (6.34) | |
Capex to Sales |
0.04 | 2.81 | 2.57 | 2.37 | |
Net Profit Margin |
(87.89%) | (73.02%) | (60.27%) | (61.32%) |
Columns are period end dates